Official ESCRS | European Society of Cataract & Refractive Surgeons
Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Corneal stability following LASIK for hyperopic correction: objective analysis by a light propagation algorithm

Search Title by author or title

Session Details

Session Title: LASIK Outcomes and Refinements

Session Date/Time: Monday 09/10/2017 | 14:30-15:50

Paper Time: 15:13

Venue: Room 4.4

First Author: : J. Alio SPAIN

Co Author(s): :    A. Gharaibeh   A. Villanueva   D. Mas   J. Espinosa           

Abstract Details


Corneal stability following LASIK for hyperopic correction, Objective analysis by a light propagation algorithm


Vissum Alicante, Spain


Forty-one patients were included in the study. All underwent hyperopic LASIK correction and completed 12 months follow up. Mean patient age was 36.2 ± 9.77 years [18 to 55]. Mean preoperative spherical equivalent was 3.75 ± 0.09 Diopters (D) [+0.625 to +8.0 D]. Corneas were analyzed with a light propagation method. We obtain the best image plane for an object at infinite provided by the cornea itself, overriding any effect from other ocular structures. Any change in this plane over the follow up period will only be related to corneal changes. This parameter was calculated at 3 and 12 months.


Calculated D power of the cornea for all patients changed from 46.7752 ± 2.0557 D (range 43.6216 to 51.7845) at three months to 46.7067 ± 2.0071 (range 43.3900-51.8380) at 12 months using a 6 mm central corneal zone (p = 0.623). Using a 9 mm central corneal zone, calculated D power changed from 46.6540± 1.9995D (range (43.1495 to 50.9500)) at three months to 46.4392± 2.2614 (range (42.6400 to 51.4000)) at 12 months (p = 0.716).


From a purely objective point of view, Cornea showed stability after LASIK for hyperopia correction over a period of 12 months. This is the first report in which Ray Tracing technique to be used to test corneal stability following Excimer laser surgery for hypermetropia.

Financial Disclosure:


Back to previous